BB-HB-331 vs tenofovir: As far as I can think, given the biology of HBV, a vector-delivered drug will HAVE to be used with the likes of tenofovir or entecavir as it will not be likely to transduce all infected liver cells, and if it doesn't then all the non-transduced infected cells will be spitting out virus to infect new liver cells. Only with tenofovir or entecavir can you completely suppress viral replication, prevent infection of new liver cells, and give time to work on shutting down cccDNA which is required to effect cure. The immune system tends to do that on its own over time if HBV remains suppressed - I suspect the eventual cure will actually involve a means that accelerates that natural process, and probably won't involve RNA/DNA interference.
- Forums
- ASX - By Stock
- BLT
- Ann: POSITIVE HBV IN VIVO DATA
Ann: POSITIVE HBV IN VIVO DATA, page-70
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online